Klinik und Poliklinik für Diagnostische und Interventionelle Radiologie
Klinikum / Johannes Gutenberg-Universität Mainz
Forschungsprojekte
Ergebnisse pro Seite:
10
2024 - 2022
A Randomized Open Label Phase 1/2 Study of INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared To Daratumumab SC, in Participants With Relapsed or Refractory Multiple Myeloma- Dr. med. Markus Munder,
- Prof. Dr. med. Georg Heß
2023 - 2030
Early treatment intensification in patients with high risk Mantle Cell Lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with Rituximab and Ibrutinib and 6 months Ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B)- Prof. Dr. med. Georg Heß
2023 - 2026
A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined With Nab-Paclitaxel Compared With Pembrolizumab Combined With Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer- Univ.-Prof. Dr. med. Marcus Schmidt,
- Dr. Katrin Almstedt
2022 - 2026
A Phase III Randomized, Open-Label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab in Combination With Tremelimumab and Enfortumab Vedotin or Durvalumab in Combination With Enfortumab Vedotin for Perioperative Treatment in Patients Ineligible for Cisplatin or Who Refuse Cisplatin Undergoing Radical Cystectomy for Muscle InvasiveBladder Cancer (VOLGA)- PD Dr. med. Maximilian Brandt,
- PD Dr. Rene Mager,
- Dr. Anita Thomas
2021 - 2030
TEDOVA Randomisierte Phase II Studie zum Vergleich eines neo-epitope basierten Vakzin OSE2101 (TEDOPI®) +/- anti-PD1 (Pembrolizumab) versus supportiver Therapie/Beobachtung in der Erhaltungstherapie bei Patientinnen mit platin-sensitiven Ovarialkarzinom-Rezidiv und kontrollierter Erkrankung nach platinbasierter Chemotherapie.- Dr. Anne-Sophie Heimes,
- Univ.-Prof. Dr. Annette Hasenburg
2021 - 2026
A Phase 3 Open-Label, Randomized Study of LOXO-305 versus Investigator Choice of BTK Inhibitor in Patients with Previously Treated BTK Inhibitor Naïve Mantle Cell Lymphoma (BRUIN-MCL-321) (#1349)- Prof. Dr. med. Georg Heß,
- Marie-Kristin Tilch
2021 - 2027
A Phase 1/2a First-in-human Study to Evaluate the Safety, Tolerability and Efficacy of IMA401, a bispecific T cell engaging receptor molecule (TCER®) in patients with recurrent and/or refractory solid tumors.- Marius Fried,
- Dr. med. Alexander Desuki